News & Updates
Filter by Specialty:

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024
Presence of mVI/S predicts HCC recurrence after liver resection
Microvascular invasion and/or satellitosis (mVI/S) is independently associated with aggressive recurrence and mortality in hepatocellular carcinoma (HCC) patients treated with liver resection (LR), a recent study has shown.
Presence of mVI/S predicts HCC recurrence after liver resection
26 Nov 2024
Is ChatGPT ready to give CRC screening recommendations?
The performance of ChatGPT in determining appropriate colorectal cancer (CRC) screening recommendations is relatively poor, with inconsistent responses in several questions, reports a study.
Is ChatGPT ready to give CRC screening recommendations?
20 Nov 2024
Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.